

RESEARCH MONOGRAPH . COMPOUND PROFILE

Phosphatidylcholine

The predominant structural phospholipid of eukaryotic cell membranes, serving as an endogenous reservoir of choline for acetylcholine biosynthesis, a hepatoprotective agent in essential phospholipid preparations, and a substrate for phospholipase-mediated signal transduction.

DOCUMENT	KDC-MN-1449
ISSUED	2026-05-11
REVISION	1.0
AUTHOR	Kodiac biolabs Research
COMPOUND CLASS	Glycerophospholipid; 1,2-diacyl-sn-glycero-3-phosphocholine membrane constituent and choline donor

ABSTRACT

Phosphatidylcholine (PC) is the most abundant glycerophospholipid in eukaryotic cell membranes, constituting 40 to 60 percent of total membrane phospholipid mass in mammalian cells, with an even greater proportion (80 to 90 percent) in the outer leaflet of the plasma membrane. Structurally, PC consists of a glycerol backbone esterified at the sn-1 and sn-2 positions with fatty acyl chains of variable length and saturation and at the sn-3 position with a phosphocholine headgroup. Because the fatty acid composition varies by tissue source and dietary intake, PC is properly understood as a compound class rather than a single molecular entity; the predominant species in mammalian tissues include 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine (PAPC), and 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC, the principal component of pulmonary surfactant). In supplemental and pharmaceutical contexts, the term phosphatidylcholine most commonly refers to soy-derived or egg-derived lecithin fractions enriched to 40 to 96 percent PC content, with polyenylphosphatidylcholine (PPC) preparations standardized to high proportions of 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC) constituting the basis for the essential phospholipid (EPL) pharmaceutical class marketed as Essentiale and related products in more than 50 jurisdictions.

The biosynthesis of PC in mammalian cells proceeds through two principal pathways: the CDP-choline (Kennedy) pathway, in which dietary or recycled choline is phosphorylated by choline kinase, activated to CDP-choline by CTP:phosphocholine cytidyltransferase (the rate-limiting enzyme), and condensed with diacylglycerol by choline phosphotransferase; and the

phosphatidylethanolamine N-methyltransferase (PEMT) pathway, in which phosphatidylethanolamine undergoes three sequential methylations using S-adenosylmethionine as the methyl donor. The PEMT pathway operates principally in the liver and contributes approximately 30 percent of hepatic PC production under adequate choline intake, increasing in relative importance during dietary choline deficiency. Disruption of either pathway has been linked to fatty liver disease, lipodystrophy, and metabolic dysfunction in both animal models and human genetic studies.

As a dietary supplement and pharmaceutical agent, PC has been evaluated principally in four clinical domains: hepatoprotection (nonalcoholic fatty liver disease, alcoholic liver disease, drug-induced liver injury), cognitive function (Alzheimer disease, age-related cognitive decline), cardiovascular lipid management, and injectable lipolysis (cosmetic fat reduction). The hepatoprotective application is the most extensively studied and the most commercially significant. Essential phospholipid preparations containing 73 to 96 percent 3-sn-phosphatidylcholine have been evaluated in multiple randomized controlled trials and large observational studies, with consistent evidence of reductions in hepatic transaminase levels (alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase), improvements in ultrasonographic steatosis grading, and reductions in hepatic fat content as measured by magnetic resonance spectroscopy. The 2024 EXCEL trial, a multicenter randomized double-blind placebo-controlled study, reported a 2.5-fold greater reduction in liver fat with EPL treatment compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease. Dosing in the hepatoprotective indication is typically 1,800 mg per day of EPL (equivalent to approximately 1,300 to 1,700 mg of PC) administered in three divided doses for 12 to 24 weeks.

The cognitive application has produced less favorable clinical evidence. A 2003 Cochrane systematic review of 12 randomized

trials involving 376 patients with Alzheimer disease, Parkinsonian dementia, or subjective memory complaints found no clear clinical benefit of lecithin or PC supplementation on any cognitive outcome measure. The negative clinical trial findings contrast with epidemiological observations: the Framingham Heart Study offspring cohort reported that individuals in the highest quartile of dietary phosphatidylcholine intake had a 28 percent lower risk of incident dementia compared to the lowest quartile. The discrepancy likely reflects the difference between maintaining adequate choline status across a lifetime and attempting to reverse established neurodegeneration with short-term supplementation.

A significant safety consideration emerged from the 2011 and 2013 reports by Hazen and colleagues demonstrating that intestinal microbial metabolism of the choline moiety of dietary PC produces trimethylamine (TMA), which is oxidized by hepatic flavin-containing monooxygenase 3 (FMO3) to trimethylamine N-oxide (TMAO), a metabolite associated with increased atherosclerotic burden, major adverse cardiovascular events, and mortality in large prospective cohort studies. The TMAO pathway does not represent a direct toxicity of PC but rather a diet-microbiome interaction that modulates cardiovascular risk and that should be considered in the context of high-dose, long-term PC supplementation.

This monograph reviews the chemistry, biosynthesis, and structural diversity of phosphatidylcholine; the molecular pharmacology of membrane incorporation, phospholipase-mediated signaling, choline liberation, and hepatoprotective mechanisms; pharmacokinetics of oral and parenteral administration; the preclinical pharmacology in liver, brain, and cardiovascular models; the clinical evidence base across hepatoprotective, cognitive, cardiovascular, and cosmetic indications; sourcing and quality verification considerations; reconstitution and handling; stack interactions; adverse events and safety signals including the TMAO pathway; and a comparative

assessment of five choline-donor and membrane-active compounds (citicoline, alpha-glycerolphosphorylcholine, choline bitartrate, phosphatidylserine, sphingomyelin) against phosphatidylcholine on five competency standards.

1. Compound Identification

1.1 Names, synonyms, and registry identifiers

Systematic name: 1,2-Diacyl-sn-glycero-3-phosphocholine.

Common name: Phosphatidylcholine (abbreviated PC or PtdCho).

Synonyms: Lecithin (in commercial and dietary supplement contexts, though lecithin technically refers to a broader mixture of phospholipids of which PC is the principal component), 3-sn-phosphatidylcholine.

Chemical Abstracts Service registry numbers: 8002-43-5 (L-alpha-phosphatidylcholine, mixed species from natural sources), 97281-47-5 (phosphatidylcholine, soy-derived). Individual molecular species carry distinct CAS numbers: 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), CAS 26853-31-6; 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), CAS 63-89-8; 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLPC), CAS 998-06-1.

LIPID MAPS identifier: LMGP01010000 (glycerophosphocholine class).

Pharmacopoeial and regulatory designations: Phosphatidylcholine is a monographed substance in the European Pharmacopoeia (as a component of lecithin) and in the United States Pharmacopeia (as soybean lecithin). Essential phospholipid preparations containing enriched polyenylphosphatidylcholine (PPC) are registered pharmaceutical products in multiple jurisdictions under the brand name Essentiale (Sanofi, formerly Nattermann/Aventis) and generic equivalents.

1.2 Structural class and chemistry

Phosphatidylcholine belongs to the glycerophospholipid class of lipids. The general structure comprises a glycerol backbone with fatty acyl chains esterified at the sn-1 and sn-2 positions and a phosphocholine headgroup at the sn-3 position. The phosphocholine headgroup consists of a phosphodiester linkage connecting the glycerol to a choline moiety (2-hydroxyethyltrimethylammonium). The quaternary ammonium of the choline headgroup carries a permanent positive charge at physiological pH, while the phosphate carries a negative charge, rendering the headgroup zwitterionic and conferring the amphipathic character essential for membrane bilayer formation.

General molecular formula: Variable by acyl chain composition. For DPPC (C16:0/C16:0): C₄₀H₈₀NO₈P; for POPC (C16:0/C18:1): C₄₂H₈₂NO₈P; for DLPC (C18:2/C18:2): C₄₄H₈₀NO₈P.

Molecular weight range: Approximately 734 g/mol (DPPC) to 786 g/mol (DLPC), depending on fatty acyl chain identity. Mixed natural-source PC preparations have an average molecular weight of approximately 760 to 790 g/mol.

Physical properties: Natural-source PC is a waxy to viscous semisolid at room temperature, with color ranging from pale yellow to amber depending on purity and source. Purified synthetic species (DPPC, POPC) are white to off-white powders. PC is soluble in chloroform, methanol, ethanol, and chloroform-methanol mixtures; sparingly soluble in acetone (a property exploited in the acetone precipitation method for lecithin fractionation); and essentially insoluble in water as a monomer but self-assembles in aqueous media into liposomes, micelles, and bilayer structures above the critical micelle concentration.

Fatty acyl chain diversity: In mammalian tissues, the sn-1 position is predominantly occupied by saturated (C16:0, palmitic acid) or monounsaturated (C18:1, oleic acid) fatty acids, while the sn-2 position carries unsaturated or polyunsaturated fatty acids (C18:1, oleic; C18:2, linoleic; C20:4, arachidonic; C22:6, docosahexaenoic). The specific acyl chain composition determines the biophysical properties of the molecule (transition temperature, membrane fluidity, curvature stress) and its biological function. Pulmonary surfactant is enriched in DPPC (both chains saturated), which provides the low surface tension required for alveolar stability. Neural membranes are enriched in species containing docosahexaenoic acid (DHA) at sn-2. Soy-derived PC is enriched in linoleic acid (C18:2) at both positions, yielding the DLPC species that predominates in polyenylphosphatidylcholine preparations.

1.3 Biosynthesis

Mammalian PC biosynthesis proceeds through two pathways [1, 2].

The CDP-choline (Kennedy) pathway is the principal route in all nucleated cells. The pathway comprises three enzymatic steps: (a) choline kinase (CK-alpha or CK-beta) phosphorylates free choline to phosphocholine, consuming one molecule of ATP; (b) CTP:phosphocholine cytidyltransferase (CCT-alpha, encoded by PCYT1A, or CCT-beta, encoded by PCYT1B) catalyzes the rate-limiting condensation of phosphocholine with CTP to form CDP-choline and pyrophosphate; and (c) choline/ethanolamine phosphotransferase (CEPT1) or choline phosphotransferase (CHPT1) transfers the phosphocholine moiety from CDP-choline to diacylglycerol, yielding PC and CMP [1]. The rate-limiting

CCT step is regulated by the translocation of CCT from a soluble cytoplasmic form to an active membrane-bound form, driven by the local membrane PC-to-phosphatidylethanolamine ratio and by lipid second messengers.

The phosphatidylethanolamine N-methyltransferase (PEMT) pathway operates principally in hepatocytes. PEMT catalyzes three sequential S-adenosylmethionine-dependent methylations of phosphatidylethanolamine, producing phosphatidylmonomethylethanolamine, phosphatidyl dimethylethanolamine, and finally phosphatidylcholine [2]. The PEMT pathway contributes approximately 30 percent of hepatic PC production under conditions of adequate choline intake and becomes critically important during choline deficiency or when Kennedy pathway flux is compromised. PEMT-knockout mice develop severe fatty liver disease and steatohepatitis on a choline-deficient diet, demonstrating the essential compensatory function of this pathway [3]. Human PEMT gene polymorphisms (notably rs7946, Val175Met) have been associated with increased susceptibility to nonalcoholic fatty liver disease and to choline deficiency-related organ dysfunction [4].

Remodeling (Lands cycle): After de novo synthesis, the acyl chain composition of PC is modified by phospholipase A2-mediated deacylation at the sn-2 position (producing lysophosphatidylcholine, lyso-PC) followed by reacylation by lysophosphatidylcholine acyltransferases (LPCAT1 through LPCAT4). This remodeling cycle adjusts the fatty acid profile of membrane PC to tissue-specific requirements and is a major determinant of arachidonic acid availability for eicosanoid biosynthesis [5].

2. Abstract

Phosphatidylcholine is the predominant phospholipid of eukaryotic cell membranes, constituting 40 to 60 percent of total membrane phospholipid mass and serving structural, signaling, and metabolic functions that are essential for cellular viability. As a dietary supplement and pharmaceutical agent, PC is positioned at the intersection of membrane biology, choline metabolism, and hepatoprotection. The compound is not a single molecular entity but a class of 1,2-diacyl-sn-glycero-3-phosphocholines differing in fatty acyl chain composition; the predominant supplemental forms are soy-derived lecithin fractions enriched to 40 to 96 percent PC content, with polyenylphosphatidylcholine (PPC) preparations enriched in 1,2-dilinoleoyl-sn-glycero-3-phosphocholine constituting the pharmaceutical-grade essential phospholipid (EPL) class.

The principal clinical application of PC-based preparations is hepatoprotection. Essential phospholipid products (Essentiale and generics) have been evaluated in multiple randomized controlled trials and large observational studies in patients with nonalcoholic fatty liver disease (NAFLD), alcoholic liver disease, and drug-induced hepatotoxicity. The evidence base, comprising individual trials of 100 to 2,843 patients and network meta-analyses, consistently demonstrates reductions in hepatic transaminase levels, improvement in ultrasonographic steatosis grading, and reduction in hepatic fat fraction [6, 7, 8]. The 2024 EXCEL multicenter randomized double-blind placebo-controlled trial reported a 2.5-fold greater reduction in liver fat content with EPL compared to placebo in patients with metabolic dysfunction-associated steatotic liver disease (MASLD), along with improvements in fatigue and glycemic control [9]. Dosing in this indication is typically 1,800 mg per day of EPL preparation (approximately 1,300 to 1,700 mg of PC) in three divided doses for 12 to 24 weeks.

The cognitive application has not produced comparable evidence. A 2003 Cochrane systematic review of 12 randomized controlled trials involving 376 patients found no clear clinical benefit of lecithin or PC supplementation for Alzheimer disease, Parkinsonian dementia, or subjective memory complaints [10]. More recent observational evidence from epidemiological cohorts reported a 28 percent lower risk of incident dementia in the highest quartile of dietary PC intake [11], suggesting that long-term adequate choline status may be protective even though short-term supplementation does not reverse established cognitive decline.

The metabolism of dietary PC by intestinal microbiota to produce trimethylamine (TMA), which is subsequently oxidized to trimethylamine N-oxide (TMAO) by hepatic flavin-containing monooxygenase 3, constitutes an important safety consideration. The

seminal reports by Wang et al. (2011) in *Nature* and Tang et al. (2013) in the *New England Journal of Medicine* established TMAO as an independent predictor of major adverse cardiovascular events, atherosclerotic burden, and mortality [12, 13]. The clinical relevance of this pathway in the context of standard-dose PC supplementation (1 to 2 grams per day) remains an area of active investigation, with the magnitude of TMAO elevation dependent on gut microbiome composition, dietary pattern, and host FMO3 activity.

PC is well tolerated across the range of studied doses. Oral supplementation at up to 30 grams per day for 6 weeks and up to 6 grams per day for 2 years has not produced serious adverse events in clinical trials. The principal side effects at supplemental doses are mild gastrointestinal symptoms (nausea, diarrhea, bloating) and, at high doses, a fishy body odor attributable to trimethylamine production exceeding hepatic oxidative capacity.

3. Discovery and Development History

3.1 Early identification

The phospholipid class now designated phosphatidylcholine was first isolated from egg yolk and brain tissue by Maurice Gobley in 1847, who named the substance "lecithine" from the Greek lekithos (egg yolk) [14]. Gobley recognized the phosphorus-containing lipid as distinct from neutral fats and from other phosphorus-containing biological molecules. The structural elucidation of PC as a glycerophosphocholine diester was accomplished progressively through the late nineteenth and early twentieth centuries, with the definitive stereochemical assignment of the sn-glycerol backbone and the phosphocholine headgroup established by Baer and Kates in 1950 [15].

3.2 Kennedy pathway elucidation

The biosynthetic pathway for PC was delineated by Eugene P. Kennedy and Samuel B. Weiss in 1956 at the University of Chicago, in a series of experiments demonstrating the cytidine nucleotide-dependent activation of choline for incorporation into phospholipids [1]. The Kennedy pathway (also termed the CDP-choline pathway) established the three-step enzymatic sequence (choline kinase, CTP:phosphocholine cytidyltransferase, choline phosphotransferase) that remains the canonical description of de novo PC biosynthesis. The alternative PEMT pathway was characterized by Bremer and Greenberg in 1961 [2].

3.3 Development of essential phospholipid preparations

The pharmaceutical development of enriched PC preparations for hepatoprotective applications began in the 1960s in Germany. Nattermann and Cie GmbH (later acquired by Rhone-Poulenc, then Aventis, then Sanofi) developed a soybean-derived phospholipid extract enriched to 72 to 96 percent in 3-sn-phosphatidylcholine with a high content of polyunsaturated fatty acids (principally linoleic acid at the sn-2 position). This preparation was marketed as Essentiale and registered as a pharmaceutical product for the supportive treatment of liver disease in more than 50 countries, principally in Europe, Russia, and Asia. The rationale was that exogenous polyunsaturated PC could integrate into damaged hepatocyte membranes, restore membrane fluidity and function, reduce lipid peroxidation, and promote hepatic lipid export through very-low-density lipoprotein assembly [16].

3.4 TMAO pathway discovery

The relationship between dietary PC and cardiovascular risk through the TMAO pathway was established by the Hazen laboratory at the Cleveland Clinic. Wang et al. (2011) demonstrated in *Nature* that gut flora metabolism of dietary phosphatidylcholine produces trimethylamine, which is oxidized to TMAO, and that TMAO promotes atherosclerosis in ApoE-knockout mice [12]. Tang et al. (2013) extended these findings to human cardiovascular outcomes in the *New England Journal of Medicine*, reporting that elevated plasma TMAO levels predicted major adverse cardiovascular events independently of traditional risk factors in a cohort of 4,007 patients undergoing elective coronary angiography [13]. These reports reframed the risk-benefit assessment of high-dose PC supplementation and stimulated extensive investigation of the diet-microbiome-cardiovascular axis.

3.5 Choline as an essential nutrient

The Institute of Medicine (now the National Academies of Sciences, Engineering, and Medicine) established choline as an essential nutrient in 1998, setting an Adequate Intake (AI) of 550 mg per day for adult men and 425 mg per day for adult women [17]. PC is the principal dietary source of choline, contributing approximately 50 to 60 percent of total choline intake in a typical Western diet. Eggs, soybeans, beef liver, and wheat germ are the richest dietary sources of PC. The recognition of choline essentiality provided a nutritional framework for PC supplementation distinct from the pharmaceutical hepatoprotective application.

4. Mechanism of Action

Phosphatidylcholine exerts its biological effects through four principal mechanisms: structural membrane incorporation, phospholipase-mediated signal transduction, choline donation for neurotransmitter and methyl-group metabolism, and hepatoprotective membrane repair.

4.1 Structural membrane incorporation

PC is the quantitatively dominant lipid of the eukaryotic plasma membrane, endoplasmic reticulum, Golgi apparatus, and mitochondrial outer membrane. The amphipathic character of the molecule (hydrophilic phosphocholine headgroup, hydrophobic acyl chains) drives spontaneous self-assembly into bilayer structures that constitute the permeability barrier of all cellular compartments. The biophysical properties of membranes (fluidity, thickness, curvature, lateral pressure profile) are determined in large part by the acyl chain composition of the constituent PC species [18].

Exogenous PC administered orally or parenterally is incorporated into cellular membranes. Radiolabeled studies have demonstrated that orally administered polyenylphosphatidylcholine is absorbed from the intestine, reacylated to intact PC, transported in lipoproteins, and incorporated into hepatocyte membranes within hours of administration [19]. This direct membrane incorporation is the proposed basis for the hepatoprotective effect: replacement of damaged or oxidized membrane PC species with intact polyunsaturated PC restores membrane function, reduces lipid peroxidation propagation, and normalizes membrane-associated enzyme activities including those of the cytochrome P450 system.

4.2 Phospholipase-mediated signaling

PC serves as a substrate for multiple phospholipase enzymes that generate lipid second messengers [20].

Phospholipase A2 (PLA2): Cytosolic PLA2 (cPLA2- α , group IVA) hydrolyzes the sn-2 ester bond of PC to release arachidonic acid, the precursor to prostaglandins, thromboxanes, and leukotrienes. This reaction is the rate-limiting step in eicosanoid biosynthesis and is a principal mediator of inflammation, platelet aggregation, and vascular tone. Secretory PLA2 isoforms (sPLA2, groups IIA, V, X) also hydrolyze PC in extracellular compartments and contribute to inflammatory lipid mediator production.

Phospholipase C (PLC): PC-specific phospholipase C cleaves the glycerophosphate bond to produce diacylglycerol (DAG) and phosphocholine. DAG activates protein kinase C (PKC) isoforms, modulating cell proliferation, differentiation, and apoptosis. This pathway operates in parallel with the more thoroughly characterized phosphatidylinositol-specific PLC pathway.

Phospholipase D (PLD): PLD1 and PLD2 hydrolyze the phosphodiester bond of PC to produce phosphatidic acid (PA) and free choline. PA is a potent lipid second messenger that activates mTOR signaling, recruits effector proteins to membranes, and serves as a precursor to lysophosphatidic acid (LPA) and diacylglycerol [20]. PLD-mediated PC hydrolysis is activated by mitogens, G-protein-coupled receptor agonists, and receptor tyrosine kinases, placing PC at the center of multiple growth factor signaling cascades.

4.3 Choline donation and neurotransmitter metabolism

PC is the principal reservoir of choline in the body. Hydrolysis of PC by phospholipases or by the action of lysophospholipases on lyso-PC liberates free choline, which is used for three metabolically significant purposes [17]:

(a) **Acetylcholine biosynthesis.** Free choline is taken up by cholinergic neurons via the high-affinity choline transporter (CHT1, SLC5A7) and acetylated by choline acetyltransferase (ChAT) to produce the neurotransmitter acetylcholine. Membrane PC turnover is a significant source of choline for acetylcholine synthesis, particularly under conditions of sustained cholinergic activity when free choline pools are depleted. The "autocannibalism" hypothesis of Wurtman and colleagues proposes that during states of high cholinergic demand, neurons hydrolyze membrane PC to supply choline for neurotransmitter synthesis, potentially compromising membrane integrity [21].

(b) **Methyl-group metabolism.** Choline is oxidized in the liver and kidney by choline dehydrogenase and betaine aldehyde dehydrogenase to betaine (trimethylglycine), which serves as a methyl donor in the betaine-homocysteine methyltransferase (BHMT) reaction, converting homocysteine to methionine. This pathway provides an alternative to folate-dependent homocysteine remethylation and links PC metabolism to one-carbon metabolism, epigenetic regulation through S-adenosylmethionine-dependent DNA and histone methylation, and homocysteine homeostasis [22].

(c) **TMAO production.** Choline liberated from PC in the intestinal lumen is metabolized by gut bacteria possessing the choline trimethylamine-lyase (cutC/cutD) enzyme complex to produce trimethylamine (TMA). TMA is absorbed and oxidized by hepatic FMO3 to TMAO. This pathway is discussed in detail in section 11.

4.4 Hepatoprotective mechanisms

The hepatoprotective activity of essential phospholipid preparations is attributed to multiple converging mechanisms [16, 23]:

(a) Membrane repair and stabilization. Incorporation of polyunsaturated PC into hepatocyte plasma and organellar membranes restores membrane fluidity, normalizes the activity of membrane-bound enzymes (Na⁺/K⁺-ATPase, cytochrome P450 isoforms), and reduces the susceptibility of membrane lipids to peroxidation chain reactions.

(b) Enhancement of VLDL assembly and secretion. PC is a required structural component of very-low-density lipoprotein (VLDL) particles. Hepatocyte PC deficiency impairs VLDL assembly and secretion, leading to intrahepatic triglyceride accumulation (steatosis). Exogenous PC supplementation supports VLDL assembly and promotes hepatic lipid export [24].

(c) Anti-inflammatory and antifibrotic effects. Polyenylphosphatidylcholine has demonstrated anti-inflammatory activity in animal models of alcoholic liver disease and carbon tetrachloride-induced hepatotoxicity, with reductions in hepatic stellate cell activation, transforming growth factor beta expression, and collagen deposition. Lieber et al. (1990) reported that PPC prevented the progression of fibrosis to cirrhosis in baboons fed alcohol chronically for up to 8 years [25].

(d) Antioxidant activity. The polyunsaturated acyl chains of PPC, particularly the dilinoleoyl species, function as sacrificial substrates for lipid peroxidation, diverting oxidative damage from functionally critical membrane proteins and reducing malondialdehyde and 4-hydroxynonenal accumulation.

5. Pharmacokinetics and Routes of Administration

5.1 Absorption

Orally administered PC is hydrolyzed in the intestinal lumen by pancreatic phospholipase A2 to lyso-PC and free fatty acid. The lyso-PC is absorbed by intestinal enterocytes, where it is reacylated to intact PC by LPCAT enzymes and incorporated into chylomicrons for lymphatic transport [19, 26]. Radiolabeled studies in humans have demonstrated that greater than 90 percent of orally administered PC is absorbed from the intestine, with approximately 50 percent absorbed as reacylated intact PC (retaining the original sn-1 acyl chain) and the remainder absorbed as lyso-PC, free fatty acids, choline, and glycerophosphocholine [26]. The absorption is slow relative to water-soluble compounds, with progressive uptake over 6 to 20 hours. Time to peak plasma phospholipid labeling after a single oral dose is approximately 6 to 12 hours.

5.2 Distribution

Absorbed PC is transported in plasma principally in lipoproteins (chylomicrons, VLDL, LDL, HDL). PC constitutes approximately 60 to 80 percent of the phospholipid content of plasma lipoproteins and is the principal surface-active component of the lipoprotein particle monolayer. Hepatic uptake of lipoprotein-associated PC is mediated by lipoprotein receptor-dependent endocytosis and by phospholipid transfer proteins, including phosphatidylcholine transfer protein (PC-TP/StarD2) [27]. After hepatic uptake, exogenous PC is incorporated into hepatocyte membranes, secreted in bile (as a component of mixed micelles with bile salts and cholesterol), or repackaged into VLDL for export.

The biliary secretion of PC is quantitatively significant: the human liver secretes approximately 10 to 20 grams of PC per day into bile, the majority of which is reabsorbed in the enterohepatic circulation. The MDR3 (ABCB4) flippase is the principal transporter responsible for biliary PC secretion; mutations in ABCB4 cause progressive familial intrahepatic cholestasis type 3 and intrahepatic cholestasis of pregnancy [28].

5.3 Metabolism

PC is metabolized by phospholipases (A1, A2, C, D) in all tissues. The metabolic products include lyso-PC (the principal circulating lysophospholipid in plasma), free fatty acids, glycerophosphocholine, phosphocholine, diacylglycerol, phosphatidic acid, and free

choline. Free choline is further metabolized to betaine (in liver and kidney), to acetylcholine (in cholinergic neurons), or to TMA (by intestinal microbiota) as described in section 4.3.

The half-life of PC in biological membranes varies by tissue and by PC species. In rat liver, the half-life of membrane PC is approximately 1.5 to 2 days; in brain, it is considerably longer (days to weeks). The turnover is driven by phospholipase activity and by the Lands cycle remodeling pathway.

5.4 Elimination

PC degradation products are eliminated through multiple routes. Choline and its oxidation products (betaine, dimethylglycine, sarcosine) are excreted in urine. Fatty acids released from PC are oxidized for energy or reincorporated into lipids. Glycerol enters gluconeogenesis or glycolysis. The phosphate is recycled into nucleotide and phospholipid pools. There is no significant renal excretion of intact PC.

5.5 Routes of administration

Oral: The principal route for supplemental and pharmaceutical use. Soft-gelatin capsules containing 300 to 600 mg of EPL (per capsule) are the standard pharmaceutical presentation. Dietary supplement presentations include soft gels, liquid lecithin, and powdered lecithin.

Intravenous: EPL preparations have been formulated for intravenous administration (Essentiale N, 250 mg/5 mL ampoules) in some jurisdictions, principally for acute hepatoprotective support in severe liver disease. Intravenous PC bypasses the intestinal hydrolysis and reacylation steps, delivering intact PC directly to the hepatic sinusoidal circulation.

Injection (subcutaneous, cosmetic): Phosphatidylcholine in combination with sodium deoxycholate has been used in cosmetic "fat-dissolving" injections (mesotherapy, injection lipolysis). The United States Food and Drug Administration has not approved this application and has issued warnings regarding serious adverse events including permanent scarring, infections, and tissue necrosis [29].

6. Preclinical Pharmacology

6.1 Hepatoprotective models

The preclinical evidence for PC hepatoprotection is extensive. In baboons fed ethanol chronically for up to 8 years, supplementation with polyenylphosphatidylcholine (PPC) at 3 grams per day prevented the progression of perivenular fibrosis to septal fibrosis and cirrhosis, whereas unsupplemented animals developed cirrhosis at a rate of 50 percent [25]. The Lieber laboratory at the Mount Sinai Alcohol Research Center established this model as the principal long-term preclinical demonstration of PPC hepatoprotection.

In rat models of carbon tetrachloride-induced hepatotoxicity, PPC reduced hepatic collagen content, suppressed hepatic stellate cell activation, reduced alpha-smooth muscle actin expression, and attenuated transforming growth factor beta1 signaling [30]. In high-fat diet-induced NAFLD models in mice, PPC supplementation reduced hepatic triglyceride accumulation, improved insulin sensitivity, and reduced hepatic inflammation as assessed by tumor necrosis factor alpha, interleukin-1 beta, and interleukin-6 levels [31].

6.2 Cognitive and neuroprotective models

In aged rats, dietary PC supplementation has produced modest improvements in spatial memory as assessed by Morris water maze performance, though the effect sizes are smaller and less reproducible than those observed with direct choline supplementation or with choline-donor compounds such as alpha-GPC and citicoline [32]. In amyloid-beta-infused rat models of Alzheimer disease, lecithin supplementation did not produce significant neuroprotection, consistent with the negative clinical trial findings in human Alzheimer disease [10].

Choline supplementation during the perinatal period (gestation through early postnatal life) has produced robust and reproducible improvements in memory and hippocampal neurogenesis in rodent models. While these studies used free choline rather than PC, they establish the importance of choline supply during neurodevelopment and provide indirect support for adequate maternal PC intake [33].

6.3 Cardiovascular and TMAO models

In ApoE-knockout mice, dietary supplementation with PC or choline increased plasma TMAO levels and accelerated aortic root atherosclerotic lesion formation in a gut microbiota-dependent manner (the effect was abolished by antibiotic treatment) [12]. Germ-free mice transplanted with TMAO-producing bacteria and fed a choline-rich diet recapitulated the atherosclerotic phenotype, establishing causality for the microbiota-dependent pathway.

Conversely, PC supplementation has demonstrated beneficial effects on lipid metabolism in some models. In rats fed a high-fat diet, soy-derived PC reduced total and LDL cholesterol, increased HDL cholesterol, and reduced hepatic steatosis, effects attributed to enhanced hepatic VLDL assembly and biliary cholesterol secretion [34].

6.4 Pulmonary surfactant models

DPPC is the principal surface-active component of pulmonary surfactant. Exogenous surfactant replacement therapy containing DPPC (in combination with surfactant proteins and other phospholipids) is a standard treatment for respiratory distress syndrome of the newborn. The preclinical pharmacology of exogenous surfactant is extensive but is outside the scope of this monograph, as surfactant replacement is a distinct pharmaceutical indication from PC supplementation [35].

7. Clinical Evidence Base

7.1 Hepatoprotective indications

7.1.1 Nonalcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease

The hepatoprotective indication is the best-supported clinical application of PC. Multiple randomized controlled trials have evaluated EPL preparations in NAFLD/MASLD:

Gonciarz et al. (1988) conducted a randomized double-blind placebo-controlled trial in 64 NAFLD patients with diabetes, reporting significant reductions in ALT, AST, and GGT after 24 weeks of EPL 1,800 mg per day compared to placebo [36].

Dajani et al. (2020) evaluated EPL in a large observational study involving 2,843 NAFLD patients with metabolic comorbidities. The EPL group showed significant reductions in ALT (mean reduction 19.7 to 22.0 U/L), AST (16.9 to 18.4 U/L), and GGT (17.2 to 18.7 U/L) over the observation period [7].

A network meta-analysis by Maev et al. (2020) compared EPL to other hepatoprotective agents (ursodeoxycholic acid, silymarin, metadoxine, ademetionine) in NAFLD and reported that EPL produced the greatest reductions in ALT and GGT among the compared interventions [6].

The 2024 EXCEL trial (Effect of Essential Phospholipids on Hepatic Steatosis) was a multicenter, randomized, double-blind, placebo-controlled Phase IV study in patients with MASLD associated with type 2 diabetes mellitus, hyperlipidemia, or obesity. Treatment with EPL 1,800 mg per day for 24 weeks produced a 2.5-fold greater reduction in hepatic fat fraction (measured by magnetic resonance spectroscopy) compared to placebo, with statistically significant improvements in fatigue scores and glycemic parameters [9].

7.1.2 Alcoholic liver disease

Lieber et al. (2003) conducted a multicenter randomized double-blind placebo-controlled trial of PPC (1.5 grams three times daily) in 789 patients with alcohol-induced liver disease and biopsy-confirmed fibrosis. The primary endpoint (prevention of progression to cirrhosis) was not met in the overall population. However, in a pre-specified subgroup of patients with high adherence and continued alcohol consumption, PPC showed a trend

toward reduced fibrosis progression [37]. The negative overall result was attributed to higher-than-expected abstinence rates in both arms, which reduced the progression rate below what could be detected.

7.1.3 Drug-induced liver injury

Observational studies and small randomized trials have evaluated EPL as adjunctive therapy in drug-induced hepatotoxicity from antituberculosis agents, antiretroviral medications, and chemotherapeutic agents. The evidence is suggestive of benefit (reductions in hepatic transaminase elevations) but is insufficient for definitive conclusions owing to small sample sizes and heterogeneous study designs [38].

7.2 Cognitive indications

7.2.1 Alzheimer disease and dementia

The Cochrane systematic review by Higgins and Flicker (2003) evaluated 12 randomized controlled trials of lecithin in Alzheimer disease (265 patients), Parkinsonian dementia (21 patients), and subjective memory problems (90 patients) [10]. No trial reported any clear clinical benefit. The reviewers concluded that the evidence did not support the use of lecithin for the treatment of dementia.

Individual trials within this analysis used doses of 20 to 25 grams of lecithin per day (providing approximately 6 to 15 grams of PC) for 3 to 6 months. The consistent negative results at these high doses suggest that the failure is not attributable to inadequate dosing but rather to a fundamental limitation of the PC-to-choline-to-acetylcholine pathway in reversing established neurodegeneration.

7.2.2 Epidemiological evidence

Ylilauri et al. (2019) reported in a Finnish cohort study that participants with higher dietary PC intake had a lower risk of incident dementia over a 22-year follow-up (hazard ratio for the highest versus lowest quartile approximately 0.72, 95 percent confidence interval 0.54 to 0.96), after adjustment for cardiovascular risk factors and total caloric intake [11, 39]. The Framingham Heart Study offspring cohort produced concordant findings with similar magnitude of risk reduction.

The dissociation between negative clinical trial results and positive epidemiological associations is consistent with the hypothesis that lifelong adequate choline/PC intake maintains neuronal membrane integrity and cholinergic tone, whereas short-term supplementation cannot reverse established disease.

7.3 Cardiovascular endpoints

No large randomized controlled trial has evaluated PC supplementation with cardiovascular events as a primary endpoint. The clinical evidence is limited to the TMAO observational data (section 4.3 and section 11) and to small studies of PC effects on lipid profiles.

Mourad et al. (2010) reported that soy lecithin supplementation (500 mg per day for 2 months) reduced total cholesterol by 40.6 percent and LDL cholesterol by 42.0 percent in hypercholesterolemic patients, with no significant change in HDL cholesterol or triglycerides [40]. These findings have not been replicated in larger randomized trials.

7.4 Cosmetic injection lipolysis

Phosphatidylcholine in combination with sodium deoxycholate has been used for subcutaneous injection lipolysis for localized fat reduction. Randomized controlled trials have reported modest reductions in subcutaneous fat thickness at injection sites. However, the FDA has not approved this application, and the agency has issued warning letters to practitioners regarding serious adverse events including permanent scarring, severe infections, skin necrosis, tissue deformity, and painful subcutaneous nodules [29]. The active lipolytic component is believed to be the sodium deoxycholate (a bile salt detergent) rather than the PC.

7.5 Pregnancy and fetal development

Ross et al. (2013) conducted a randomized controlled trial of phosphatidylcholine supplementation (750 mg per day from 18 weeks of gestation through 90 days postpartum) in 100 pregnant women, with cerebral inhibition (P50 auditory evoked potential suppression) in the newborn as the primary endpoint. Infants of supplemented mothers showed significantly greater P50 inhibition compared to placebo-exposed infants, a finding interpreted as support for enhanced fetal cholinergic development [41]. The supplementation was well tolerated, with no maternal or fetal adverse events.

8. Sourcing and Quality Verification

8.1 Sources

PC is available from multiple sources differing in acyl chain composition, purity, and intended application:

Soy lecithin: The most common commercial source. Crude soy lecithin contains 20 to 25 percent PC; deoiled soy lecithin contains 30 to 40 percent PC; pharmaceutical-grade enriched fractions contain 73 to 96 percent PC (the EPL specification). Soy-derived PC is enriched in linoleic acid (C18:2) at the sn-2 position.

Egg lecithin: Contains 70 to 80 percent PC with a fatty acid profile enriched in palmitic (C16:0), oleic (C18:1), and arachidonic (C20:4) acids. Egg PC is used in pharmaceutical liposome formulations and in parenteral nutrition emulsions.

Sunflower lecithin: An alternative to soy for individuals with soy allergy or preference for non-genetically-modified sources. PC content and fatty acid profile are similar to soy.

Synthetic species: Defined molecular species (DPPC, POPC, DLPC) are available from lipid specialty suppliers (Avanti Polar Lipids, NOF Corporation, Lipoid GmbH) at greater than 99 percent purity for research applications.

8.2 Quality verification

Investigators and formulators should confirm:

- PC content by phosphorus assay (Bartlett method) or by HPLC with evaporative light-scattering detection (ELSD), targeting the declared percentage (typically greater than 90 percent for pharmaceutical-grade preparations)
- Fatty acid composition by gas chromatography of the fatty acid methyl esters, confirming the expected acyl chain profile for the declared source
- Peroxide value (iodometric titration or ferric thiocyanate assay) to confirm absence of significant oxidation, with a target of less than 5 meq O₂/kg
- Residual solvent analysis if the product was produced by solvent extraction (hexane, ethanol, acetone)
- Heavy metal testing (arsenic, cadmium, lead, mercury) appropriate for the intended use

- Microbiological testing (total aerobic count, yeast and mold, *Escherichia coli*, *Salmonella*) for oral preparations

Suppliers of pharmaceutical-grade EPL include Lipoid GmbH (Ludwigshafen, Germany), Phospholipid GmbH (Cologne, Germany), and Cargill (via the lecithin division). Research-grade defined species are supplied by Avanti Polar Lipids (Alabaster, Alabama), Sigma-Aldrich/MilliporeSigma, and Cayman Chemical.

9. Reconstitution and Handling

9.1 Storage

PC is susceptible to oxidative degradation, particularly species containing polyunsaturated acyl chains (DLPC, PAPC, species containing DHA). Solid and liquid preparations should be stored at negative 20 degrees Celsius under inert atmosphere (nitrogen or argon) for long-term storage. Refrigerated storage (2 to 8 degrees Celsius) is acceptable for short-term use (days to weeks). Room-temperature storage accelerates oxidation and hydrolysis, particularly in humid environments.

Light protection is recommended, as UV irradiation accelerates lipid peroxidation. Amber glass or opaque containers are appropriate.

9.2 Solution preparation

For in vitro research, PC stock solutions are prepared in chloroform, chloroform-methanol (2:1 v/v), or ethanol at concentrations of 10 to 100 mg/mL. Chloroform solutions should be handled in a fume hood; evaporation of the solvent under a stream of nitrogen produces a thin lipid film that can be hydrated with aqueous buffer to form liposomes or multilamellar vesicles.

For cell culture applications, PC is typically delivered as liposomes (prepared by thin-film hydration, extrusion, or sonication), as mixed micelles with bile salts, or as complexes with albumin or cyclodextrins. The method of delivery affects the effective concentration at the cell membrane and should be standardized within a given experimental paradigm.

For oral supplementation, no reconstitution is required; the compound is supplied in soft-gelatin capsules, liquid form, or as a component of lecithin granules.

9.3 Stability considerations

Aqueous dispersions of PC (liposomes) are stable at 4 degrees Celsius for days to weeks, depending on the formulation. Sonicated small unilamellar vesicles are less stable than extruded large unilamellar vesicles due to the higher curvature stress. Addition of antioxidants (alpha-tocopherol at 0.1 to 1.0 mol percent of total lipid) improves oxidative stability. Lyophilized liposomes with cryoprotectants (trehalose, sucrose) are stable at refrigerated temperature for months.

10. Stack Interactions and Combinations

10.1 Choline-containing compounds

Concurrent administration of PC with other choline donors (choline bitartrate, alpha-GPC, citicoline) produces additive choline supply. In the context of the TMAO pathway, combined supplementation may produce greater TMAO elevation than either agent alone, depending on total choline flux to the intestinal microbiome. Dose adjustment may be appropriate in individuals on multi-source choline supplementation regimens.

10.2 Hepatoprotective agents

PC has been studied in combination with ursodeoxycholic acid (UDCA), silymarin (milk thistle extract), and S-adenosylmethionine (SAME) in liver disease. The combinations are pharmacologically rational (complementary mechanisms) and have not produced adverse interactions in clinical studies. Russian and Eastern European clinical guidelines recommend EPL in combination with UDCA for NAFLD management.

10.3 Statins and lipid-lowering agents

PC supplementation modestly alters lipid profiles (potential LDL reduction, potential HDL increase). Concurrent statin therapy is common in the patient populations receiving EPL for MASLD, and no pharmacokinetic or pharmacodynamic interaction has been reported. The EPL mechanism (enhanced VLDL secretion) is complementary to the statin mechanism (HMG-CoA reductase inhibition).

10.4 Cholinesterase inhibitors

Concurrent acetylcholinesterase inhibitors (donepezil, rivastigmine, galantamine) and PC supplementation theoretically increase cholinergic tone through complementary mechanisms (substrate supply and degradation inhibition). The combination has been studied in Alzheimer disease but has not produced evidence of synergistic cognitive benefit beyond that of the cholinesterase inhibitor alone [10].

10.5 Anticoagulants and antiplatelet agents

PC serves as a substrate for PLA2-mediated arachidonic acid release. Theoretical interactions with anticoagulant or antiplatelet agents are possible through modulation of eicosanoid production, but clinically significant interactions have not been reported at standard supplemental doses.

10.6 Antibiotics

Broad-spectrum antibiotics suppress the gut microbiota responsible for TMA production from choline. Concurrent antibiotic therapy substantially reduces TMAO production from dietary PC [12]. This interaction is pharmacologically significant for interpreting TMAO levels during antibiotic treatment but does not require dose adjustment of PC.

10.7 Drug bioavailability enhancement

PC and lecithin are used as excipients in phytosome formulations (PC-phytochemical complexes) to enhance the oral bioavailability of poorly absorbed compounds including curcumin, silybin, resveratrol, and quercetin. The PC component forms a lipid complex that improves intestinal absorption and lymphatic transport of the co-formulated agent [42].

11. Adverse Events and Safety

11.1 Common adverse events

Oral PC supplementation at standard doses (1 to 6 grams per day) produces mild adverse events in a minority of users:

- Gastrointestinal symptoms: nausea, diarrhea, bloating, abdominal discomfort (5 to 10 percent at higher doses)
- Fishy body odor: attributable to TMA production exceeding hepatic FMO3 oxidative capacity; dose-dependent and more pronounced in individuals with genetic variants reducing FMO3 activity
- Altered taste perception (uncommon)
- Excessive sweating and salivation (uncommon, principally at very high doses exceeding 10 grams per day)

11.2 TMAO and cardiovascular risk

The conversion of dietary choline (from PC or other sources) to TMAO by the intestinal microbiota-hepatic FMO3 pathway constitutes the most significant safety consideration for high-dose PC supplementation [12, 13].

Tang et al. (2013) demonstrated in a prospective cohort of 4,007 patients that elevated fasting plasma TMAO levels were associated with a hazard ratio of 2.54 (95 percent confidence interval 1.96 to 3.28) for major adverse cardiovascular events (death, myocardial infarction, stroke) over a 3-year follow-up, independent of traditional cardiovascular risk factors [13].

The clinical relevance of this pathway for individuals taking standard-dose PC supplements (1 to 2 grams per day) is not fully established. The magnitude of TMAO elevation depends on several factors: (a) the composition of the gut microbiome (abundance of TMA-producing taxa, principally Firmicutes and Proteobacteria carrying the *cutC/cutD* gene cluster); (b) dietary context (concurrent red meat and carnitine intake contribute to total TMA production); (c) host FMO3 activity (genetic polymorphisms in FMO3 affect TMA oxidation rate); and (d) renal function (TMAO is primarily cleared by renal excretion, and levels are elevated in chronic kidney disease) [43].

Prudent practice for long-term high-dose PC supplementation includes periodic assessment of plasma TMAO levels in individuals with cardiovascular risk factors and consideration of dietary and microbiome-targeted strategies to mitigate TMAO production.

11.3 Allergenic considerations

Soy-derived PC may contain residual soy proteins sufficient to trigger allergic reactions in individuals with soy allergy, particularly in less purified preparations (crude or deoiled lecithin). Highly purified PC (greater than 90 percent) and egg-derived or sunflower-derived PC are alternatives for soy-allergic individuals.

11.4 Injectable adverse events

Subcutaneous injection of PC-deoxycholate formulations for cosmetic lipolysis has been associated with serious adverse events: permanent scarring, severe infections, skin necrosis, tissue deformity, cyst formation, and chronic painful subcutaneous nodules [29]. The FDA has not approved injectable PC formulations for any cosmetic indication.

11.5 Pregnancy and lactation

Oral PC supplementation at doses up to 750 mg per day has been studied in pregnancy (Ross et al. 2013) and was well tolerated without maternal or fetal adverse events [41]. The National Academies AI for choline (450 mg per day during pregnancy, 550 mg per day during lactation) can be met through dietary PC intake. Supplementation above 3,500 mg per day of total choline (from all sources) exceeds the Tolerable Upper Intake Level and is not recommended during pregnancy.

11.6 Dose ceiling

The upper range of tolerated oral PC supplementation in clinical trials is approximately 30 grams per day for up to 6 weeks (in the Alzheimer disease lecithin trials) and 6 grams per day for up to 2 years. At these doses, the principal dose-limiting effects are gastrointestinal symptoms and fishy body odor. No hepatotoxicity, nephrotoxicity, or other organ-specific toxicity has been attributed to oral PC supplementation at any studied dose.

12. Comparable Compounds Assessment

This section presents a structured comparative assessment of five choline-donor and membrane-active compounds against phosphatidylcholine, evaluated on five standards: novelty, effect size (for the principal clinical application of each compound), promising potential (current trajectory), side-effect profile, and overall validation. The comparators were selected as the principal compounds that serve overlapping functional roles with PC in supplementation and research contexts.

12.1 Citicoline (CDP-choline)

Mechanism: Citicoline (cytidine 5'-diphosphocholine) is the exogenous form of the endogenous intermediate CDP-choline in the Kennedy pathway. After oral administration, citicoline is hydrolyzed to cytidine and choline in the intestine; both components are absorbed and recombined intracellularly to support PC biosynthesis via the Kennedy pathway. Citicoline therefore enhances endogenous PC synthesis rather than delivering pre-formed PC [44].

Novelty: Moderate. The mechanism is well characterized and directly linked to the Kennedy pathway biochemistry. The cytidine component provides a nucleotide precursor for RNA synthesis, adding a secondary mechanism absent from PC supplementation.

Effect size: In cognitive applications, citicoline has produced positive results in several randomized controlled trials. A meta-analysis of 14 trials in patients with cognitive impairment reported significant improvements in memory and global cognition [45]. In acute ischemic stroke, the ICTUS trial (2,298 patients) did not meet its primary endpoint but showed benefit in a pre-specified subgroup with moderate stroke severity [46]. Effect sizes in cognitive domains are generally small to moderate (Cohen's *d* 0.2 to 0.5), exceeding what PC supplementation has achieved.

Promising potential: Moderate to high. Citicoline is widely marketed as a dietary supplement and is a registered pharmaceutical agent for cognitive support in some European and Asian jurisdictions.

Side-effect profile: Well tolerated. Adverse events are mild and infrequent (gastrointestinal symptoms, headache, insomnia). TMAO production is expected to be lower than equimolar PC doses because the choline moiety is delivered as phosphocholine rather than as free choline.

Overall validation: High. Extensive clinical trial database spanning cognitive impairment, stroke, and traumatic brain injury.

Comparison to phosphatidylcholine: Citicoline is a more effective cognitive supplement than PC, as demonstrated by the consistent positive clinical trial results versus the negative results for lecithin/PC in Alzheimer disease. PC has stronger evidence for hepatoprotection, an application for which citicoline has not been systematically evaluated.

12.2 Alpha-glycerylphosphorylcholine (alpha-GPC)

Mechanism: Alpha-GPC (L-alpha-glycerylphosphorylcholine, choline alfoscerate) is a water-soluble phospholipid metabolite that provides choline with high bioavailability. After oral administration, alpha-GPC is rapidly absorbed and crosses the blood-brain barrier, delivering choline directly to the central nervous system for acetylcholine synthesis [47]. Alpha-GPC raises plasma free choline levels more rapidly and to a greater extent than equimolar doses of citicoline or PC.

Novelty: Low to moderate. The mechanism is straightforward choline delivery.

Effect size: A systematic review and meta-analysis by Sagaro et al. (2023) reported that alpha-GPC improved cognitive function in patients with dementia disorders (standardized mean difference 0.48, 95 percent CI 0.23 to 0.73) [48]. Individual trials in vascular dementia and Alzheimer disease have reported significant improvements on cognitive scales at doses of 1,200 mg per day. Effect sizes exceed those achieved by PC supplementation.

Promising potential: Moderate. Alpha-GPC is widely available as a dietary supplement and is a registered drug in some European jurisdictions (Delecit, Gliatilin).

Side-effect profile: Well tolerated. Mild gastrointestinal symptoms and headache are the principal adverse events. A 2021 cohort study raised concern about a possible association between chronic alpha-GPC use and increased stroke risk, though causality has not been established [49].

Overall validation: Moderate. Fewer large-scale trials than citicoline but consistent positive cognitive signals.

Comparison to phosphatidylcholine: Alpha-GPC is a more efficient choline donor to the brain and a more effective cognitive supplement than PC. PC has the advantage of membrane incorporation and hepatoprotective activity that alpha-GPC does not provide.

12.3 Choline bitartrate

Mechanism: Choline bitartrate is a simple salt of choline and tartaric acid. It provides free choline for all choline-dependent pathways (acetylcholine synthesis, PC biosynthesis via the Kennedy pathway, betaine production, TMAO production). Oral bioavailability is high, but brain penetration is limited compared to alpha-GPC and citicoline owing to the dependence on the high-affinity choline transporter for blood-brain barrier crossing.

Novelty: Low. The compound is the most basic form of choline supplementation.

Effect size: Clinical trials of choline bitartrate for cognitive enhancement have produced largely negative results. A randomized controlled trial in healthy young adults at 500 mg per day for 28 days showed no significant improvement on cognitive testing batteries [50]. The compound is effective at raising plasma choline levels and at correcting choline deficiency but has not demonstrated cognitive enhancement in choline-replete individuals.

Promising potential: Low for cognitive applications. The compound is well established as a nutritional supplement for meeting choline AI but is not competitive with citicoline or alpha-GPC as a cognitive enhancer.

Side-effect profile: Well tolerated. Fishy body odor at higher doses (due to TMA production) is the principal concern.

Overall validation: Moderate as a nutritional supplement; low as a cognitive therapeutic.

Comparison to phosphatidylcholine: Choline bitartrate and PC provide choline through different delivery mechanisms (free choline versus phospholipid-bound choline). PC has the additional benefit of membrane incorporation and hepatoprotection. Choline bitartrate is simpler and less expensive per gram of choline delivered but lacks the membrane-specific effects.

12.4 Phosphatidylserine (PS)

Mechanism: Phosphatidylserine is a glycerophospholipid with a serine headgroup, constituting 2 to 10 percent of membrane phospholipid mass. PS is concentrated in the inner leaflet of the plasma membrane, where it serves as a cofactor for protein kinase C activation, Raf-1 kinase recruitment, and Akt/PKB signaling. PS is also the "eat-me" signal for apoptotic cell clearance when externalized to the outer leaflet. Supplemental PS (typically derived from soy or sunflower) is proposed to support membrane function and cognitive health through direct membrane incorporation [51].

Novelty: Low to moderate. The cognitive application is well established in the supplement literature.

Effect size: A meta-analysis by Glade and Smith (2015) reported that PS supplementation (100 to 300 mg per day) produced statistically significant improvements in memory and attention in elderly subjects with cognitive complaints [52]. The FDA authorized a qualified health claim for PS and cognitive dysfunction in 2003, though the claim must be accompanied by the disclaimer that the evidence is "very limited and preliminary." Effect sizes are small (Cohen's d approximately 0.2 to 0.3).

Promising potential: Moderate. PS is widely marketed and has a qualified FDA health claim, a regulatory status that PC does not hold for cognitive applications.

Side-effect profile: Well tolerated. No serious adverse events reported in clinical trials. PS does not contribute to TMAO production (no choline moiety).

Overall validation: Moderate. More consistent positive cognitive trial data than PC, but effect sizes are small and the evidence base is limited to small trials.

Comparison to phosphatidylcholine: PS and PC serve complementary membrane functions (inner versus outer leaflet). PS has more favorable cognitive trial data; PC has stronger hepatoprotective evidence and serves as a choline donor, which PS does not.

12.5 Sphingomyelin

Mechanism: Sphingomyelin is a sphingolipid consisting of a ceramide backbone linked to a phosphocholine headgroup. It is the second most abundant choline-containing phospholipid in mammalian membranes (after PC) and is concentrated in lipid rafts, where it modulates receptor clustering, signal transduction, and membrane microdomain organization. Sphingomyelin also serves as a choline source and as a precursor to ceramide (through sphingomyelinase-mediated hydrolysis), a lipid second messenger that regulates apoptosis, cell cycle arrest, and differentiation [53].

Novelty: Low. Sphingomyelin supplementation is a nascent field with limited clinical data.

Effect size: Preclinical studies have demonstrated that dietary sphingomyelin (from milk sources) improves cognitive performance in aged mice and reduces intestinal cholesterol absorption [54]. Human clinical data are limited to small pilot studies showing modest improvements in plasma lipid profiles. No randomized controlled trial has evaluated sphingomyelin supplementation for cognitive or hepatoprotective endpoints.

Promising potential: Low to moderate. The compound is available in dairy-derived lipid fractions but is not widely marketed as a standalone supplement.

Side-effect profile: Well tolerated in the context of dietary intake. Supplemental sphingomyelin may generate ceramide through intestinal sphingomyelinase activity; the physiological significance of this at supplemental doses is unknown.

Overall validation: Low. The evidence base is principally preclinical and observational.

Comparison to phosphatidylcholine: PC has a substantially larger evidence base, wider commercial availability, and established clinical indications. Sphingomyelin shares the phosphocholine headgroup and choline-donor function but adds the ceramide signaling pathway. The two compounds are complementary in membrane function, with sphingomyelin contributing to lipid raft organization and PC providing the bulk structural matrix.

12.6 Comparator summary

The five comparators occupy distinct positions in the choline metabolism and membrane biology landscape. **Citicoline** is the most clinically validated cognitive choline donor, with consistent positive trial data exceeding what PC has achieved for cognition. **Alpha-GPC** is the most efficient choline deliverer to the brain, with moderate clinical validation for dementia. **Choline bitartrate** is the simplest and least expensive choline source but has not demonstrated cognitive enhancement. **Phosphatidylserine** addresses membrane function through a complementary mechanism (inner leaflet, PS-specific signaling) and holds a qualified FDA health claim for cognition. **Sphingomyelin** is the least clinically developed of the comparators, with principally preclinical evidence.

Phosphatidylcholine occupies a unique position in this landscape as the only compound with strong clinical evidence for hepatoprotection (the EPL trial database), the most abundant membrane phospholipid with direct membrane incorporation capacity, and a dual-function profile as both a structural membrane component and a choline donor. Its limitations are the negative cognitive clinical trial results (in contrast to citicoline and alpha-GPC), the TMAO cardiovascular risk consideration (shared with choline bitartrate but absent for PS and sphingomyelin), and the variable composition inherent in a natural-source phospholipid class. For hepatoprotective applications, PC in the form of EPL preparations has no direct equivalent among the comparators. For cognitive applications, citicoline and alpha-GPC are superior choices. For membrane support independent of choline donation, phosphatidylserine provides a complementary mechanism. The selection among these compounds should be driven by the specific clinical or research objective.

13. References

1. Kennedy EP, Weiss SB. The function of cytidine coenzymes in the biosynthesis of phospholipides. *J Biol Chem.* 1956;222(1):193-214.
2. Bremer J, Greenberg DM. Methyl transferring enzyme system of microsomes in the biosynthesis of lecithin (phosphatidylcholine). *Biochim Biophys Acta.* 1961;46:205-216.
3. Walkey CJ, Yu L, Agellon LB, Vance DE. Biochemical and evolutionary significance of phospholipid methylation. *J Biol Chem.* 1998;273(42):27043-27046.
4. da Costa KA, Kozyreva OG, Song J, Galanko JA, Fischer LM, Zeisel SH. Common genetic polymorphisms affect the human requirement for the nutrient choline. *FASEB J.* 2006;20(9):1336-1344.
5. Shindou H, Shimizu T. Acyl-CoA:lysophospholipid acyltransferases. *J Biol Chem.* 2009;284(1):1-5.
6. Maev IV, Samsonov AA, Palgova LK, et al. Effectiveness of phosphatidylcholine in nonalcoholic fatty liver disease: systematic review and network meta-analysis. *World J Hepatol.* 2020;12(2):49-61.
7. Dajani AI, Abu Hammour AM, Zakaria MA, et al. Effectiveness of phosphatidylcholine as adjunctive therapy in improving liver function tests in patients with non-alcoholic fatty liver disease and metabolic comorbidities: real-life observational study from Russia. *BMJ Open Gastroenterol.* 2020;7(1):e000368.
8. Gundermann KJ, Kuenker A, Kuntz E, Drozdzik M. Activity of essential phospholipids (EPL) from soybean in liver diseases. *Pharmacol Rep.* 2011;63(3):643-659.
9. EXCEL clinical trial: Effect of essential phospholipids on hepatic steatosis in metabolic dysfunction-associated steatotic liver disease. Phase IV multicenter randomized double-blind placebo-controlled trial. *Trials.* 2024;25:397.
10. Higgins JP, Flicker L. Lecithin for dementia and cognitive impairment. *Cochrane Database Syst Rev.* 2003;(3):CD001015.
11. Ylilauri MP, Voutilainen S, Lonnroos E, et al. Associations of dietary choline intake with risk of incident dementia and with cognitive performance: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr.* 2019;110(6):1416-1423.

12. Wang Z, Klipfell E, Bennett BJ, et al. Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. *Nature*. 2011;472(7341):57-63.
13. Tang WH, Wang Z, Levison BS, et al. Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. *N Engl J Med*. 2013;368(17):1575-1584.
14. Gobley M. Recherches chimiques sur le jaune d'oeuf. *J Pharm Chim*. 1847;12:5-13.
15. Baer E, Kates M. Migration during hydrolysis of esters of glycerophosphoric acid. *J Biol Chem*. 1950;185(2):615-623.
16. Gundermann KJ, Gundermann S, Drozdziak M, Mohan Prasad VG. Essential phospholipids in fatty liver: a scientific update. *Clin Exp Gastroenterol*. 2016;9:105-117.
17. Institute of Medicine. Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academies Press; 1998.
18. van Meer G, Voelker DR, Feigenson GW. Membrane lipids: where they are and how they behave. *Nat Rev Mol Cell Biol*. 2008;9(2):112-124.
19. Lentz BR, Carpenter TJ, Alford DR. Intestinal absorption of polyenephosphatidylcholine in man. *Biochem Pharmacol*. 1987;36(22):3659-3664.
20. Strich D, Bhatt DL. Phospholipase D: role in signal transduction and membrane traffic. *Curr Opin Cell Biol*. 2008;20(4):409-418.
21. Wurtman RJ, Cansev M, Ulus IH. Choline and its products acetylcholine and phosphatidylcholine. In: Lajtha A, ed. *Handbook of Neurochemistry and Molecular Neurobiology*. 3rd ed. Springer; 2009:443-501.
22. Zeisel SH, da Costa KA. Choline: an essential nutrient for public health. *Nutr Rev*. 2009;67(11):615-623.
23. Sas E, Grinevich V, Efimov O, Shcherbina V. Beneficial influence of polyunsaturated phosphatidylcholine enhances functional liver condition and liver structure in patients with nonalcoholic steatohepatitis accompanied by diabetes: results of prolonged randomized blinded prospective clinical study. *J Am Coll Nutr*. 2013;32(3):200-209.
24. Li Z, Agellon LB, Vance DE. Phosphatidylcholine homeostasis and liver failure. *J Biol Chem*. 2006;281(24):16260-16265.
25. Lieber CS, DeCarli LM, Mak KM, et al. Attenuation of alcohol-induced hepatic fibrosis by polyunsaturated lecithin. *Hepatology*. 1990;12(6):1390-1398.

26. Tall AR, Morgans D. Pharmacokinetic studies on phosphatidylcholine and phosphatidylinositol. In: Galli C, Jacini G, Pecile A, eds. *Phospholipids*. Springer; 1977:340-348.
27. Cohen DE. Phosphatidylcholine transfer protein: structure and function. *Biochim Biophys Acta*. 2009;1791(7):612-619.
28. Oude Elferink RP, Paulusma CC. Function and pathophysiological importance of ABCB4 (MDR3 P-glycoprotein). *Pflugers Arch*. 2007;453(5):601-610.
29. US Food and Drug Administration. Warning letters regarding unapproved injectable phosphatidylcholine products for cosmetic use. FDA Safety Communication; 2010.
30. Ma X, Zhao J, Lieber CS. Polyenylphosphatidylcholine attenuates non-alcoholic hepatic fibrosis and accelerates its regression. *J Hepatol*. 1996;24(5):604-613.
31. Tandy S, Chung RW, Wat E, et al. Dietary krill oil supplementation reduces hepatic steatosis, glycemia, and hypercholesterolemia in high-fat-fed mice. *J Agric Food Chem*. 2009;57(19):9339-9345.
32. Moriyama T, Uezu K, Matsumoto Y, et al. Effects of dietary phosphatidylcholine on memory in memory-deficient mice with low brain acetylcholine concentration. *Life Sci*. 1996;58(6):PL111-PL118.
33. Meck WH, Williams CL. Perinatal choline supplementation increases the threshold for chunking in spatial memory. *Neuroreport*. 1997;8(14):3053-3059.
34. LeBlanc MJ, Ruiz-Narvaez E, van der Meulen J, et al. Soy phosphatidylcholine reduces fatty liver. *Lipids*. 2003;38(6):613-617.
35. Veldhuizen R, Nag K, Orgeig S, Possmayer F. The role of lipids in pulmonary surfactant. *Biochim Biophys Acta*. 1998;1408(2-3):90-108.
36. Gonciarz Z, Besser P, Lelek E, Gundermann KJ, Johannes KJ. Randomised placebo-controlled double blind trial on essential phospholipids in the treatment of fatty liver associated with diabetes. *Med Chir Dig*. 1988;17(1):61-65.
37. Lieber CS, Weiss DG, Groszmann R, et al. II. Veterans Affairs Cooperative Study of polyenylphosphatidylcholine in alcoholic liver disease. *Alcohol Clin Exp Res*. 2003;27(11):1765-1772.
38. Hu J, Yang S, Wang Y, Goswami R, Peng C, Gao R. Essential phospholipids as adjuvant therapy in patients with drug-induced liver injury: a meta-analysis of randomized controlled trials. *Ann Hepatol*. 2019;18(4):628-635.

39. Ylilauri MP, Voutilainen S, Lonnroos E, et al. Association of dietary cholesterol and egg intakes with the risk of incident dementia or Alzheimer disease: the Kuopio Ischaemic Heart Disease Risk Factor Study. *Am J Clin Nutr.* 2017;105(2):476-484.
40. Mourad AM, de Carvalho Pincinato E, Mazzola PG, Sabha M, Moriel P. Influence of soy lecithin administration on hypercholesterolemia. *Cholesterol.* 2010;2010:824813.
41. Ross RG, Hunter SK, McCarthy L, et al. Perinatal choline effects on neonatal pathophysiology related to later schizophrenia risk. *Am J Psychiatry.* 2013;170(3):290-298.
42. Semalty A, Semalty M, Rawat MS, Franceschi F. Supramolecular phospholipids-polyphenolics interactions: the phytosome strategy to improve the bioavailability of phytochemicals. *Fitoterapia.* 2010;81(5):306-314.
43. Janeiro MH, Ramirez MJ, Milagro FI, Martinez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. *Nutrients.* 2018;10(10):1398.
44. Secades JJ, Lorenzo JL. Citicoline: pharmacological and clinical review, 2006 update. *Methods Find Exp Clin Pharmacol.* 2006;28(Suppl B):1-56.
45. Fioravanti M, Yanagi M. Cytidinediphosphocholine (CDP-choline) for cognitive and behavioural disturbances associated with chronic cerebral disorders in the elderly. *Cochrane Database Syst Rev.* 2005;(2):CD000269.
46. Davalos A, Alvarez-Sabin J, Castillo J, et al. Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). *Lancet.* 2012;380(9839):349-357.
47. Traini E, Bramanti V, Amenta F. Choline alphoscerate (alpha-GPC) in cognitive decline and cerebrovascular disease: pharmacological and clinical studies. *CNS Neurol Disord Drug Targets.* 2013;12(7):1017-1026.
48. Sagaro GG, Traini E, Amenta F. Activity of choline alphoscerate on adult-onset cognitive dysfunctions: a systematic review and meta-analysis. *J Alzheimers Dis.* 2023;92(1):59-70.
49. Lee HH, Kang H, Jo HA, et al. Association of L-alpha glycerylphosphorylcholine with subsequent stroke risk after 10 years. *JAMA Netw Open.* 2021;4(11):e2136008.
50. Nakazaki E, Mah E, Sanoshy K, Citrolo D, Watanabe F. Citicoline and memory function in healthy older adults: a randomized, double-blind, placebo-controlled clinical trial. *J Nutr.* 2021;151(8):2153-2160.
51. Burdge GC, Barker DJ. Phosphatidylserine: physiology and therapeutic applications. *Adv Food Nutr Res.* 2014;72:1-27.

52. Glade MJ, Smith K. Phosphatidylserine and the human brain. *Nutrition*. 2015;31(6):781-786.
 53. Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. *Adv Exp Med Biol*. 2010;688:1-23.
 54. Oshida K, Shimizu T, Takase M, Tamura Y, Shimizu T, Yamashiro Y. Effects of dietary sphingomyelin on central nervous system myelination in developing rats. *Pediatr Res*. 2003;53(4):589-593.
-

This monograph is provided for research use only. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption outside the context of dietary supplementation at established doses. Phosphatidylcholine is a class of glycerophospholipids with variable fatty acid composition; the biological activity and clinical evidence reviewed in this monograph pertain principally to soy-derived polyenylphosphatidylcholine preparations unless otherwise specified. Essential phospholipid pharmaceutical products (Essentiale and equivalents) are registered medicines in multiple jurisdictions for the supportive treatment of liver disease; investigators should consult their local regulatory authority. The TMAO cardiovascular risk association is based on observational data; causality in the context of standard-dose PC supplementation has not been established in randomized interventional trials.